Nav1.8 blockers(Sodium channel protein type X alpha subunit blockers), RYR1 modulators(Ryanodine receptor 1 modulators), RYR2 modulators(Ryanodine receptor 2 modulators)

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication

Pain

Originator Organization

Cetylite Industries, Inc.

Active Organization

University of Pennsylvania School of Dental Medicine

Inactive Organization

Cetylite Industries, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC9H11NO2

InChIKeyBLFLLBZGZJTVJG-UHFFFAOYSA-N

CAS Registry94-09-7

View All Structures (2)

Clinical Trials associated with Benzocaine/Tetracaine

NCT03233737 / CompletedPhase 2

A Double-blind, Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339A) When Applied to the Gingival Mucosal Tissue in Normal Volunteers

The purpose of this study is to determine if the topical application to gingival tissue of the combination of benzocaine and tetracaine has a longer duration of local anesthetic activity than benzocaine alone.

Start Date15 Jun 2017

Sponsor / Collaborator

Cetylite Industries, Inc.

NCT02908620 / CompletedPhase 2

A Double-blind, Partial Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339-A) When Applied to the Cheek Mucosal Tissue in Normal Volunteers

The purpose of this study is to determine if the topical application to cheek tissue of the combination of benzocaine and tetracaine has a longer duration of local anesthetic activity than benzocaine alone.

Start Date07 Dec 2016

Sponsor / Collaborator

Cetylite Industries, Inc.

100 Clinical Results associated with Benzocaine/Tetracaine

100 Translational Medicine associated with Benzocaine/Tetracaine

100 Patents (Medical) associated with Benzocaine/Tetracaine

Literatures (Medical) associated with Benzocaine/Tetracaine

01 Feb 2019·Clinical TherapeuticsQ4 · MEDICINE

A Proof-of-concept Study Using Quantitative Sensory Threshold Analysis to Compare Two Intraoral Topical Anesthetics

Q4 · MEDICINE

Article

Author: Hersh, Elliot V ; Wang, Steven ; Cooper, Stephen A ; Farrar, John T ; Mousavian, Mohammad ; Giannakopoulos, Helen ; Wang, Ping ; Lesavoy, Bret ; Doyle, Geraldine ; Hutcheson, Matthew C ; Secreto, Stacey

PURPOSECTY-5339A is an investigational topical anesthetic spray containing 14% benzocaine/2% tetracaine in a metered canister. Each spray delivers ∼0.2 mL of solution. This double-blind, randomized, crossover study compared the local anesthetic effect of CTY-5339A versus 14% benzocaine alone by using 2 quantitative sensory threshold experimental pain paradigms on the maxillary gingiva: pin prick test pain intensity (PPT PI) and heat pain threshold (HPT).METHODSAmerican Society of Anesthesiology Class 1 and 2 subjects (N = 50) were enrolled in this study. To qualify for the study, subjects were tested on the anterior maxillary gingiva with both PPT and HPT. Subjects had to report a PPT PI of ≥3 on a 0 to 10 numeric pain intensity scale on 1 of 2 consecutive pin pricks separated by 10 s, with at least one score ≥4. After PPT, mean HPT following 2 ramps in the same location had to be ≤ 46.5 °C, with each ramp beginning at 35 °C and an automatic cutoff of 50.6 °C. For treatment visits, subjects were randomly administered either 1 spray of CTY-5339A or 14% benzocaine to the anterior maxillary gingiva within 3 weeks of screening and then the alternative treatment 5 days to 2 weeks later. PPT PI and HPT were recorded immediately before drug application. After drug administration, PPT PI was recorded every minute through 5 min. Commencing at 5 min, PPT PI and HPT were recorded every 5 min through 60 min. For assessment of methemoglobin concentrations, venous blood (5 mL) was drawn from the antecubital fossa both before and 60 min after drug application. Oxygen saturation was recorded via pulse oximetry at baseline and every 10 min.FINDINGSThe AUCs for pain intensity difference from 0-30 and 0-60 min after PPT and HPT differences were significantly greater (P < 0.0001) for CTY-5339A compared with 14% benzocaine. Multiple time points on the time-action curves for PPT PI difference and HPT difference statistically (P < 0.05) favored CTY-5399A. Methemoglobin and oxygen saturation levels did not change compared with baseline after dosing with either treatment.IMPLICATIONSRecommended doses of CTY-5339A provided significantly more profound and sustained local anesthesia than 14% benzocaine when applied to the maxillary gingiva. Significant changes in methemoglobin or oxygen saturation concentrations did not occur for either drug. ClinicalTrials.gov identifier: NCT03233737.

100 Deals associated with Benzocaine/Tetracaine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anesthesia	Discovery	US	Cetylite Industries, Inc.	07 Dec 2016
Pain	Discovery	US	Cetylite Industries, Inc.	07 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03233737 (CTgov)	Phase 2	Pain	75	One spray CTY-5339-A (Stage I: One Spray CTY-5339-A)	hdrawlkskj(oilneocsad) = dxcyjvuhyx nsdqcgurbj (qcgnmzdors, ibsddnpzax - eiynhmybhy) View more	-	21 Aug 2019
				One spray CTY-5339-CB (Stage I: One Spray CTY-5339-CB)	hdrawlkskj(oilneocsad) = mwliguugfi nsdqcgurbj (qcgnmzdors, sgiewpdrhe - gstbljqeqr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Benzocaine/Tetracaine

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation